ANI Pharmaceuticals (NASDAQ:ANIP) Rating Lowered to Buy at Wall Street Zen

ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday.

A number of other equities analysts have also commented on the company. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Barclays began coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They set an “overweight” rating and a $100.00 target price for the company. Guggenheim raised their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $70.49 on Friday. The firm has a market capitalization of $1.58 billion, a PE ratio of 20.98 and a beta of 0.52. ANI Pharmaceuticals has a 1 year low of $56.71 and a 1 year high of $99.50. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11. The firm’s fifty day simple moving average is $79.12 and its 200 day simple moving average is $85.26.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, SVP Ori Gutwerg sold 2,060 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $76.50, for a total value of $157,590.00. Following the completion of the sale, the senior vice president owned 84,782 shares in the company, valued at approximately $6,485,823. This trade represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Thomas Andrew Rowland sold 4,772 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total value of $357,470.52. Following the sale, the senior vice president directly owned 38,730 shares in the company, valued at approximately $2,901,264.30. This trade represents a 10.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 29,482 shares of company stock valued at $2,248,424 in the last three months. Company insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors have recently modified their holdings of ANIP. Hantz Financial Services Inc. raised its stake in shares of ANI Pharmaceuticals by 202.6% in the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 237 shares in the last quarter. Advisors Asset Management Inc. acquired a new stake in ANI Pharmaceuticals during the first quarter worth $28,000. Newbridge Financial Services Group Inc. boosted its stake in ANI Pharmaceuticals by 200.0% during the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock worth $39,000 after buying an additional 400 shares in the last quarter. Kemnay Advisory Services Inc. bought a new stake in ANI Pharmaceuticals in the 4th quarter valued at $48,000. Finally, State of Wyoming acquired a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Key ANI Pharmaceuticals News

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Zacks/analyst bullishness — A Zacks piece highlights ANIP among four biotech names to watch for upside in 2026, citing new drug approvals and pipeline progress. Another Zacks story notes the consensus of Wall Street analysts implies roughly a 44.8% upside in ANIP, which could support buying interest if fundamentals continue to improve. 4 Biotech Stocks to Watch for Potential Upside in 2026 Analysts See a 44.84% Upside in ANI (ANIP)
• Neutral Sentiment: Analyst/market coverage piece — Yahoo published a “sizing up” note after a recent share-price pullback that reviews valuation and technicals; such coverage can attract traders looking to buy a dip but doesn’t itself guarantee direction. Sizing Up ANI Pharmaceuticals After Recent Share Price Pullback
• Neutral Sentiment: Short interest data appears non‑informative — a March note shows effectively zero reported short interest (and a 0.0 days-to-cover), suggesting short activity is not currently driving the move. This item is ambiguous given the odd/empty figures provided.
• Negative Sentiment: Insider selling — Several insiders disclosed open-market sales this week: VP Meredith Cook sold 500 shares (avg ~$72.62; SEC filing), insider Christopher Mutz sold 3,162 shares (avg ~$71.64; SEC filing), and SVP Thomas Rowland sold 4,772 shares (avg ~$74.91; SEC filing). Combined, these disclosures show executives trimming positions and likely contributed to downward pressure on the stock today. Meredith Cook Form 4 Christopher Mutz Form 4 Thomas Rowland Form 4

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.